afsaneh lavasanifar, curriculum vitea - university of … · afsaneh lavasanifar, curriculum vitea...

Afsaneh Lavasanifar, Curriculum Vitea 15 A. PERSONAL INFORMATION

Name: Afsaneh Lavasanifar University Address: 2142F Katz Group/Rexall Center for Pharmacy and Health Research, University of Alberta, Edmonton, AB, Canada T6G 2E1

Tel: (780) 492-2742 Fax: (780) 492-1217 E-mail: [email protected] Internet: http://www.pharmacy.ualberta.ca/Lavasanifar_lab/ Nationality: Canadian/Iranian Language: English, Farsi

B. UNIVERSITY EDUCATION

09/1996 - 09/2001 Ph.D. Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB.

01/1983 – 06/1988 Pharm. D, Pharmacy, Tehran University of Medical Sciences, Iran.

C. PROFESSIONAL EXPERIENCE

07/2011-Present Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB

05/2009 - Present 07/2005–06/2011

Adjunct Professor, Department of Chemical and Material Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB Associate Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB

11/2001-06/2005 Assistant Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB

09/1997-09/2001 Teaching Assistant, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB

05/1994-05/1996 Formulation Consultant, Iran Daru (Pharmaceutical company), Iran

03/1992-05/1996 Lecturer in Pharmaceutics, Dr. Beheshti University of Medical Sciences, Tehran, Iran

I. BACKGROUND INFORMATION

mailto:[email protected]

http://www.pharmacy.ualberta.ca/Lavasanifar_lab/

LAVASANIFAR, AFSANEH Nov 2013

2

02/1989-02/1992 Research Scientist, Food & Drug Organization, Tehran, Iran

D. AWARDS AND HONORS 2013 TEC Edmonton, Innovation makes sense.

2009 2009 2007 2007 2006 2000

Sanofi-aventis/AFPC New Investigator Research Award; Presented by the Association of the Faculties of Pharmacy of Canada, annual meeting, Halifax, June 2009. Top 3 most cited paper in Journal of Pharmaceutical Sciences.

GlaxoSmithKline Early Career Award, Presented by the Canadian Society for Pharmaceutical Sciences (CSPS) in their 10th annual symposium in Montreal, Quebec. Top 10 most cited paper in Journal of Controlled Release in 2005. Journal of Controlled Release, Most cited paper in 2005 award. Wu Hong Poster Prize for visual presentation display at the Research Day, University of Alberta, AB, Canada.

09/2000-09/2001 Mike Wolowyk Graduate Scholarship,

2000 Association of Faculties of Pharmacy of Canada Award, University of Saskatoon, SK, Canada.

1999 American Association of Pharmaceutical Scientists, Pharmaceutics and Drug Delivery Section Annual Meeting Travelship Award, Neworleans, LA, USA.

1999 Wu Hong Poster Prize for visual presentation display at the Research Day, University of Alberta, AB, Canada.

1998 Mary Louse Imrie Graduate Students Award for poster presentation at the Annual Meeting of the American Association of Pharmaceutical Scientists in San Francisco, University of Alberta, AB, Canada.

E. PROFESSIONAL ORGANIZATION MEMBERSHIP - Canadian Society of Pharmaceutical Scientists (CSPS)

- Association of the faculties of Pharmacy in Canada (AFPC)

- American Society of Pharmaceutical Scientist (AAPS)

- Controlled Release Society (CRS)


3

A. RESEARCH INTERSTS

1. Design and development of nanotechnology products for improving response to cancer chemotherapy. Research on this topic is pursued in two avenues:

a. Development of polymeric nano-carriers for the targeted delivery of anticancer drugs. The mission of this research program is to develop innovative pharmaceuticals (with particular focus on nano-medicine) that offer bio-available, less toxic, and more effective alternativeness to current drugs in combating hard-to-treat and resistant cancers. Particular attention is paid to the development of engineered carriers that provide specific delivery of anti-cancer drugs to cellular and intracellular targets. Collaborations on this line of research are established with Dr Lai (Cross Cancer Institute), Dr Kaur and Dr Seubert (Faculty of Pharmacy). Different elements of this project have been funded by NSERC and CIHR.

b. Development of polymer based nano-carriers for the tumor targeted delivery of modulators of drug resistant. It is the objective of this research to either silence the expression or inhibit the function of oncoproteins responsible for resistance to therapy in several tumors. Collaborations are in place with Dr Uludag (Chemical and Material Engineering), Dr Lai (Cross Cancer Institute) and Dr Brocks (Faculty of Pharmacy) on this research. The research is currently funded by a collaborative research grant from NSERC/CIHR.

2. Development of new biodegradable block copolymers for mucosal and regional delivery.

This project is seeking development of a new family of biodegradable polymeric micellar delivery systems and thermo- and pH responsive hydrogels for the solubilization of poorly water soluble drugs and/or depot drug release. Collaborations with Dr Choi (Chemical and Material Engineering), Dr Unswarth (NINT and Chemical Material Engineering) and Dr Sundararaj (Chemical and Material Engineering) are pursued on this project. Different aspects of this project have been funded by AHFMR and NSERC.

3. Development of nano-delivery systems for cancer immunotherapy and immunomonitoring-

The nanoparticle delivery of therapeutic cancer vaccines to dendritic cells (DCs) for the modulation of T cell mediated immune responses constitutes is an alternative method that (in combination with targeted chemotherapy) has the potential to make an extraordinary world-wide advancement in cancer eradication. A major barrier to cancer immunotherapy is cancer-induced immune tolerance. The objective of this research is to exploit development of nanoparticulate based cancer vaccines that can provide a plat form for co-delivery of cancer antigens and adjuvants to DCs boosting immune response against cancer associated/specific antigens. A second objective under this project will seek design of tumor or DC targeted nano-delivery systems for overcoming immunotolerance against cancer vaccines. We also have an interest in the development MRI and PET nano-probes for DC and T-cell imaging in the context of cancer immunotherapy.

II. RESERCH AND SCHOLARY ACTIVITIES


4

B. RESEARCH GRANTS a. Received:

Title of the grant Source Role Total amount

Period of support

Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer

CIHR PI 100,000 10/2014-09/2015

Novel Nanoparticulate STAT3 Inhibitors for Treating Multiple Myeloma

AIHS Co-PI $750,000 04/2014-03/2017

Chemical tailoring of micelle-forming poly(ethylene oxide)-b-poly ester copolymers for drug delivery

NSERC PI $125,000 04/2014-03/2019


NSERC PI $29,000 04/2013-03/2014

A Digital PCR for Biomedical Engineering Application

NSERC (RTI) Co-PI $79,600 04/2013-04/2014

Tumor targeted polymeric nanocarriers for oncogene silencing therapy of metastatic breast cancer

CIHR1/ACF2 PI $ 100,000 10/2012-09/2013

Fluorescence lifetime imaging and fluorescence polarization for elucidation of molecular level events: peptide self-assembly, NP disassembly in cells, and phage binding.

NSERC (RTI) Co-PI 86,288 09/2012-09/2014

An Inverse Gas Chromatographic System for the Characterization of Biopolymers

NSERC (RTI) Co-PI 63,000 09/2012-09/2014

siRNA Based Molecular Therapy for Reversal of Drug Resistance in Leukemia

Alberta Cancer Foundation

Co-PI $ 300,000 09/2011-09/2013

Nano-delivery systems for cancer immunotherapy: Modulation of the anticancer immunity at the induction and effector phases

CIHR1/ACF2 PI $ 100,000 10/2011-04/2013

Ligand Guided Polymeric Nanocarriers for tumor targeted drug and oncogene silencing therapy

CIHR1/ACF2 PI $ 100,000 04/2011-04/2012

CFI3 PI $ 377,613 09/2011-09/2012 Facility to Support the Bench-to-bedside Development of Targeted

AET4 PI $ 377,613 09/2011-09/2012


5

Drugs and Drug Delivery Systems for Improved Therapeutic Performance Application of nanotechnology in delivering targeted anti-cancer therapy

ACF2 Co-PI $ 300,000 05/2010-04/2012

Differential scanning calorimetry for the development of new pharmaceutical with improved performance

NSERC5 PI $ 73,500 04/2010-04/2011

Development of targeted nano-carriers for the delivery of RNAi therapeutics

AET4 PI $ 50,000 09/2010-02 /2011

A New Approach for Sensitization of Chemoresistant Cancers to Drug Therapy

CIHR1/NSERC5

Co-PI $ 100,000 05/2009-05/2010


NSERC5 PI 120,300 05/2008-04/2013

Evaluation of current stability of Thioguanine suspension

Capital Health PI $ 6,981 07/2008-12/2008

Tumor Targeted nano-delivery systems for improving response to chemotherapy in cancer

CIHR1 PI $ 149,452 09/2008-04/2011

Nano-delivery systems for cancer immunotherapy: Modulation of the anticancer immunity at the induction and effector phases

CIHR1 PI* $ 540,617 01/2007-09/2011

Beckman Coulter Cell Lab Quanta SC Flow Cytometer

AHFMR6 Co-PI $ 90,000 04/2007-04/2008

Biodegradable block copolymers as injectable hydrogels for depot drug delivery

AHFMR6 PI $ 15,000 09/2007-12/2007

Ligand guided polymeric nano-carriers for targeted drug and vaccine delivery in cancer

NSERC5 PI * $ 649,707 09/2006-09/2009

Nuclear Magnetic Resonance (NMR) Facility Operator Salary/Maintenance Support and 400 MHz NMR Spectrometer System

CIHR1 Co-PI $ 495,665 04/2006-03/2011

Assessing the stability of 6-Mercaptopurine suspensions

Novopharm PI $ 7,000 01/2006-01/2012

Polymer based nanocarriers for the solubilization and controlled delivery of hydrophobic drugs

AHFMR6 PI $ 35,000 03/2005-03/2006

Molecular Biopharmaceutics, Drug CFI3-IOF Co-PI $ 50,092 08/2004-08/2010


6

Metabolism and pharmacokinetics Facility Molecular Biopharmaceutics, Drug Metabolism and pharmacokinetics Facility

CFI3 Co-PI $ 492,436 06/2003-06/2004

Waters Micromass LC Mass spectrometrySystem

AHFMR6 Co-PI $ 158,254 06/2003-06/2004


NSERC5 PI $ 125,000 05/2003-04/2008

University of Alberta Startup fund University of Alberta

PI $ 50,000 01/2002-03/2006

1Canadain Institute of Health Research (CIHR) 2 Alberta Cancer Foundation (ACF) 3 Canadian Foundation for Innovation (CFI) 4Alberta Advanced Education and Technology (AET) 5 Natural Science and Engineering Research Council of Canada (NSERC) 6Alberta Heritage Foundation for Medical Research (AHFMR) * The original PI of this grant was Dr John Samuel. I took the role of PI in this grant after his passing in April 2007. C. RESEARCH COMMUNITY a. Editorial board

1. Section Editor of Journal of Pharmacy and Pharmaceutical Sciences 2. Open Nanomedicine, Bentham Science Publishers Ltd, the Netherlands 3. Materials Sciences and Applications, Bentham Science Publishers Ltd, the Netherlands 4. Iranian Polymer Journal, Tehran, Iran.

b. Reviewer for grants

1. National Institute of Health (NIH) ad hoc member in the GDD panel, October 2012, June 2013, Feb 2014.

2. Canadian Institute of Health Research (CIHR), Terry FOX CIHR team grant, May 2011.

3. Quebec Consortium for drug delivery, Internal reviewer, 2012.

4. National Cancer Institute of Canada (NCIC). Panel G1 (Experimental Therapeutics, Medicinal Chemistry and Drug Development) February 2009, Committee member.

5. Canadian Institute of Health Research (CIHR). Pharmaceutical Sciences’ committee member, 2007, 2008, 2009, 2010, 2014.


7

6. National Science and Engineering Research Council of Canada (NSERC). External reviewer.

7. Canadian Foundation for Innovation (CFI). External Reviewer.

8. The Wellcome Trust, London. External Reviewer.

9. Saskatchewan Health Research Foundation. External Reviewer.

10. Natural Resources and Applied Sciences (NRAS), Province of British Columbia, External Reviewer.

11. The Danish Council for Independent Research | Natural Sciences, External Reviewer, 2011

c. Review for Journals 1. Pharmaceutical Research

2. Journal of Pharmaceutical Sciences

3. International Journal of Pharmaceutics

4. Biomaterials

5. Biomacromolecules

6. Journal of Pharmacy and Pharmaceutical Sciences

7. Journal of Controlled Release

8. Advanced drug delivery reviews

9. Journal of Biomedical material Research

10. Cancer Chemotherapy and Pharmacology

11. European Journal of Pharmaceutics and Biopharmacutics

12. Macromolecules

13. Molecular pharmaceutics

14. Macromolecular Bioscience

15. Macromolecular rapid communications

16. Progress in Polymer Science

17. AAPS Journal

18. Journal of Vaccum Science and Technology B

19. Daru

20. Journal of Drug Targeting

21. Open Nanomedicine

22. Applied radiation and isotopes

23. Nanomedicine


8

24. Polymeric drug delivery: Science and application

25. ACS Nano

26. Journal of drug delivery

27. Journal of biomaterial science, polymer edition

28. Material Science and Engineering C

29. Acta Biomaterialia

30. Pharmaceutical Development and Technology

31. Drug Delivery

32. Chemistry of Materials

33. Molecules

D. PUBLICATIONS a. Published/In Press Refereed Papers * Corresponding author

1. Basak Sahin; Jeremy Fife; Manoj Parmar; Juliana Valencia-Serna; Hilal Gul-Uludag; Xiaoyan Jiang; Afsaneh Lavasanifar; Michael Weinfeld; Hasan Uludag. “siRNA Therapy in Cutaneous T-cell Lymphoma Cells Using Non-Viral (Polymeric) Carriers” Biomaterials, In Press.

2. Soheila Honary, Afsaneh Lavasanifar “The Effect of Self-assembly Conditions on the Size of Di- and Triblock Copolymer Micelles: Solicitation from Response Surface Methodology” Pharmaceutical Development and Technology, In Press.

3. J Emami; M Rezazadeh; M Rostami, F Hasanzadeh; A. Emami, A Mostafavi; M Minaiyan; A Lavasanifar Co-delivery of paclitaxel and a-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy” Drug Development and Industrial Pharmacy, In Press. Available online.

4. Haddadi, Azita; Hamdy, Samar; Ghotbi, Zahra; Samuel, John; Lavasanifar, Afsaneh “Immunoadjuvant Activity of Nanoparticles Surface Modified with Mannan" Nanotechnology, In Press.

5. M, Shahin, N Safaei Nikouei and A Lavasanifar* (2014) “Polymeric micelles for pH responsive delivery of cisplatin to breast tumor cells” Journal of Drug Targeting, 22(7):629-37.

6. Q Zhang, M R Vakili , X-F Li, A Lavasanifar*, X. C Le (2014) “Polymeric Micelles for GSH Triggered Delivery of Arsenic Trioxide Derivatives to Cancer Cells” Biomaterials, 35(25)7088-100.

7. Han M, Vakili MR, Soleymani Abyaneh H. Molavi L and LavasanifarA, Mitochondrial delivery of doxorubicin via TPP modification for the reversal of drug resistance in MDA-MB-435/DOX cells. Molecular Pharmaceutics, In Press.


9

8. Hyunah Cho, Clifford S. Cho, Guilherme L. Indig, Afsaneh Lavasanifar, Mohammad Reza Vakili and Glen S. Kwon (2014) “Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. " PlosOne, 9(2)e89968.

9. Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludag H, Lavasanifar A

"Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy" Journal of Biomedical Material Research A, In Press.

10. Hoda Soleymani, Mohammad Reza Vakili, Afsaneh Lavasanifar* (2014) “The Effect of

Polymerization Method in Stereo-active Block Copolymers on the Stability of Polymeric Micelles and their Drug Release Profile” Pharmaceutical Research, 31(6)1485-500.

11. Haeri A, Sadeghian S, Rabbani S, Anvari MS, Lavasanifar A, Amini M, Dadashzadeh S.

(2013) “Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: A comparison of phospholipid micelles and liposomes” International Journal of Pharmaceutics, 455 (1-2) 320-30.

12. Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan IH, Lavasanifar A* and

Lai R* (2013) “Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against ALK+ALCL” Biomaterials, 34(34) 8718-25.

13. Shahin M, Soudy R, Aliabadi HM, Kneteman, N, Kaur K, Lavasanifar A. (2013)

“Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity” Biomaterials, 34(16) 4089-97. (The 2013 winner of the GattefosséCanada CSPS award in Lipid based drug delivery)

14. Binkhathlan, Z., Lavasanifar A* (2013) “P-glycoprotein inhibition as a therapeutic

approach for overcoming multidrug resistance in cancer: current status and future perspectives” Current Cancer Drug Targets, 13:326-346.

15. Mathews AS, Ahmed S, Shahin, M, Lavasanifar A, Kaur K*, (2013) “Peptide Modified

Polymeric Micelles Specific for Breast Cancer Cells” Bioconjugate Chemistry, 24(4):560-70.

16. Abbasi M, Lavasanifar A, Uludağ H (2013) “Recent Attempts at RNAi Mediated P-

glycoprotein Down-Regulation for Reversal of Multidrug Resistance in Cancer” Medicinal Research Reviews, 33(1)33-53.

17. Shahin M, Soudy R, Kaur K, Haitham El-Sikhry1, John M. Seubert, Lavasanifar A (2013)

“Engineered Peptides for the Development of Actively Tumor Targeted Liposomal Carriers of Doxorubicin” Cancer Letters, 334(2):284-92.

18. Xiong XB, Binkhathlan, Z., Molavi O, Lavasanifar A* (2012) “Amphiphilic block

copolymers: preparation and application in nanodrug and gene delivery” Acta

http://www.ncbi.nlm.nih.gov/pubmed/24587157

http://www.ncbi.nlm.nih.gov/pubmed/24587157

http://www.ncbi.nlm.nih.gov/pubmed?term=Haeri%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Sadeghian%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Rabbani%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Anvari%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Lavasanifar%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Amini%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23867987

http://www.ncbi.nlm.nih.gov/pubmed?term=Dadashzadeh%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23867987


10

Biomarterilia, 8(6):2017-33. (The top 25 most downloaded articles between April and June in Acta Biomaterialia).

19. Binkhathlan Z, Brocks DR, Shayeganpour A, Lavasanifar A* (2012) “Encapsulation of P-

glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin.” European Journal of Pharmaceutics and Biopharmaceutics, 81(1):142-8.

20. Falamarzian A., Xiong X.B., Uludag, H and Lavasanifar A, (2012) “Polymeric micelles

for targeted siRNA delivery” Journal of Drug Delivery Science and Technology, 22 (1) 43-54.

21. Binkhathlan Z, Elhasi S, Brocks DR, Lavasaniar A* (2012) “Characterization of the self-

assembly of poly(ethylene oxide)-poly(a-benzyl-e-carboxylate caprolactone) for the solubilization and in vivo delivery of valspodar” Current Drug Delivery, 9(2):164-71.

22. Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K*, (2011) Proteolitically Stable Cancer

Targeting Peptides with High Affinity for Breast Cancer Cells, Journal of Medicinal Chemistry, 54(21)7523-34.

23. Xiong XB, Lavasanifar A* (2011) “Traceable multifunctional polymeric micelles for co-

delivery of mdr1 siRNA and doxorubicin” ACS Nano, 28;5(6):5202-13. ((Top 20 most downloaded articles between April and June in ACS Nano)

24. Xiong XB, Falamarzian A, Garg S, Lavasanifar A* (2011) “Engineering of amphiphilic

block copolymers for polymeric micellar drug and gene delivery” Journal of Controlled Release,155(2):248-61.

25. Sung B, Prasad S, Yadav VR, Lavasanifar A, Aggarwal B.B* (2011), “Cancer and Diet:

how they are related?” Free Radical Research, 45(8):864-79.

26. Safaiee Nekoie N, Lavasanifar A (2011) “Characterization of the thermo- and pH-responsive assembly of triblock copolymers based on poly(ethylene glycol) and functionalized poly(ε-caprolactone)” Acta Biomaterilia,7(10) 3708-18.

27. Abbasi M., Aliabadi HM, Moase E, Lavasanifar A and Uludag H. (2011) “siRNA

Mediated Down-Regulation of P-glycoprotein in a Xenograft Tumor Model in NOD-SCID Mice” Pharmaceutical Research, 28(10) 2516-29.

28. Hamdy S, Haddadi A, Shayeganpour A., Samuel J, Lavasanifar A (2011) “Activation of

antigen specific T cell responses by mannan-decorated PLGA nanoparticles” Pharmaceutical Research, 28(9) 2288-301.

29. Shahin M, Ahmad S, Kaur K, Lavasanifar A (2011) “Decoration of polymeric micelles

with cancer specific peptides for active targeting of paclitaxel” Biomaterials,


11

32(22):5123-33. (Winner of a publication award from Canadian Institute of Health Research/Institute of Cancer Research).

30. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi AOS, Uludag H, Lavasanifar A

(2011) “Down-Modulation of STAT3 in B16 Melanoma by siRNA Induces Bystander Immune Response: an in vitro and in vivo Study” Translational Oncology, 4(3):178-88.

31. Hamdy S, Haddadi A, Shayeganpour A, Aliabadi HM, Lavasanifar A (2011)“The

immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies” AAPS Journal, 13(2):159-68.

32. Bahadur RKC, Landry B, Aliabadi HM, Lavasanifar A, Uludağ H (2011) “Lipid-

Substitution on Low Molecular Weight Polyethylenimine Leads to Effective Assembly of Plasmid DNA and Transgene Expression, Acta Biomaterialia, 7(5):2209-17.

33. Hamdy S, Haddadi A, Hung RW, Samuel J, Lavasanifar A (2011) “Targeting dendritic

cells with nano-particulate PLGA cancer vaccine formulations” Advanced Drug delivery Reviews, 63(10-11)943-55.

34. Hamdy S, Haddadi A, Ghotbi Z, Hung RW, Lavasanifar A (2011) “Targeted Particles for

Cancer Immunotherapy” Current Drug Delivery, 8(3)261-73.

35. Hung RW, Hamdy S, Haddadi A, Ghotbi Z, Lavasanifar A (2011) “Targeted particles for the imaging of anti-cancer immune response” Current Drug Delivery, 8(3)274-81.

36. Garg S, Xiong XB, Lu C, Lavasanifar A (2011) “Application of click chemistry for the

Preparation of Core Crosslinked Polymeric Micelles Based on Poly(ethylene oxide)-poly(ε-caprolactone)” Macromolecules, 44(7)2058-66.

37. Aliabadi, HM, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A* (2011)“Evaluation of the Stability of compounded Thioguanine suspension” American Journal of Health-System Pharmacy, 15;68(10):900-8.

38. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi S, Uludag H, Lavasanifar A.

(2010) “STAT3 Silencing in Dendritic Cells by siRNA Polyplexes Encapsulated in PLGA Nanoparticles for the Modulation of Anticancer Immune Response” Molecular Pharmaceutics,7(5)1643-1654.

39. Ahmed S, Mathews AS, Byeon N, Lavasanifar A, Kaur K*. (2010) “Peptide arrays for

screening cancer specific peptides” Analytical Chemistry, 82(18):7533-41.

40. Falamarzian A, Lavasanifar A* (2010) “Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B” Colloids & Surfaces B:Biointerfaces, 81(1)313-20.


12

41. Van Guggenberg E, Shahhosseini S, Koslowsky S, Lavasanifar A, Murray D, Mercer J* (2010) “In vitro characterization of two novel biodegradable vectors for the delivery of radiolabelled oligonucleotides” Cancer Biotherapy & Radiopharmaceuticals, 25(6) 723-731.

42. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A* (2011) “Active

targeting of dendritic cells with mannan-decorated PLGA nanoparticles” Journal of Drug Targeting, 19(4)281-292.

43. Xiong XB, Uludag H and Lavasanifar A* (2010) “Virus-mimetic polymeric micelles for

targeted siRNA delivery Biomaterials, 31(22)5886-93.

44. Binkhathlan Z, Hamdy D, Brocks DR, Lavasanifar A* (2010) “Development of a Polymeric Micellar Formulation for Valspodar and Assessment of its Pharmacokinetics in Rat” European Journal of Pharmaceutics and Biopharmaceutics, 75(2)90-5.

45. Abbasi M., Lavasanifar A., Berthiaume L, Weinfeld M and Uludağ H* (2010) “Cationic

polymer mediated small interfereing RNA delivery for permeability glycoprotein down-regulation in tumor cells” Cancer, 116(23)5544-5554.

46. Incani, V., Lin X., Lavasanifar A., Uludag H*. (2010) “Lipid and hydrophobic

modification of cationic carriers on route to superior gene vectors” Soft Matter, 6(10) 2124-2138

47. Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, El-Kadi AO* (2010)

“Validation of Bone Marrow Derived Dendritic Cells as an Appropriate Model to Study Tumor-Mediated Suppression of DC Maturation through STAT3 Hyperactivation” Journal of Pharmacy and Pharmaceutical Science, 13 (1) 21-6.

48. Falamarzian A, Lavasanifar A* (2010) “Chemical modification of hydrophobic block in

poly(ethylene oxide) poly(caprolactone) based nano-carriers: Effect on the solubilization and hemolytic activity of Amphotericin B" Macromolecular Bioscience, 10(6)648-56.

49. Shahin M, Lavasanifar A* (2010) “Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery” International Journal of Pharmaceutics. 389(1-2):213-222.

50. Patal SK, Lavasanifar A, Choi P* (2010) “Molecular dynamics study of the encapsulation

capability of a block copolymer containing three PCL blocks connected to one end of a PEO block for two classes of hydrophobic drugs with different spatial distributions of hydrogen bond donors and acceptors” Biomaterials, 31(7):1780-6.

51. Alshamsan A, Hamdy S, Samuel J, El-Kadi, O.S. Lavasanifar A*, Uludag H* (2010)

“The Induction of Tumor Apoptosis in B16 Melanoma following STAT3 siRNA Delivery with a Lipid-Substituted Polyethylenimine” Biomaterials, 31(6):1420-8. (The 2010 winner of the Gattefosse Canada / CSPS Research Award in lipid based drug delivery)


13

52. Molavi O, Mahmud A, Hamdy S, Hung R, Lai R, Samuel J, Lavasanifar A* (2010)

“Development of a poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy” Molecular Pharmaceutics, 7(2)364-74. (Cited by national Cancer Institute website, http://nano.cancer.gov/action/news/2010/feb/nanotech_news_2010-02-18d.asp)

53. Xiong XB, Ma Z, Lai R, Lavasanifar A* (2010) “The Therapeutic Response to

Multifunctional Polymeric Nano-Conjugates in the Targeted Cellular and Subcellular Delivery of Doxorubicin” Biomaterials, 31(4):757-68.

54. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* (2010) “Pharmacokinetics of

PSC 833 (Valspodar) in A Cremophor EL-Based Formulation in Rat” Xenobiotica, 40(1):55-61.

55. Patal SK, Lavasanifar A, Choi P* (2010) “Prediction of the solubility of cucurbitacin

drugs in self associating poly(ethylene oxide)-b-poly( -benzyl carboxylate -caprolactone) block copolymer with different tactiticities using molecular dynamics simulation” Biomaterials, 31(2):345-57.

56. Kanduru S, Lavasanifar A, Brocks DR* (2010) “An analytical method for cyclosporine

using liquid chromatography-mass spectrometry” Biomedical Chromatography, 24(2):148-53.

57. Patal SK, Lavasanifar A, Choi P* (2009) "Roles of Non-polar and Polar Intermolecular

Interactions in the Improvement of the Drug Loading Capacity of PEO-b-PCL with Increasing PCL Content for two Hydrophobic Cucurbitacin Drugs" Biomacromolecules, 10(9):2584-91.

58. Incani V, Lin X, Lavasanifar A, Uludag H* (2009) “Relationship between the extent of

lipid substitution on Poly(L-Lysine) and DNA delivery efficiency” ACS Applied Materials & Interfaces, 1(4) 841-848.

59. Mahmud A, Patal SK, Molavi O, Choi P, Samuel J, Lavasanifar A* (2009) “Self

associating poly(ethylene oxide)-b-poly(ε-caprolactone) block copolymers with pendent cholesterol groups for the solubilization and delivery of STAT-3 inhibitor Cucurbitacin I” Biomacromolecules, 10 (3), 471–478.

60. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludag H* (2009)

“Formulation and Delivery of siRNA by Oleic Acid and Stearic Acid Modified Polyethylenimine” Molecular Pharmaceutics, 2;6(1):121-133.

61. Xiong XB, Uludag H, Lavasanifar A* (2009) “Biodegradable amphiphilic poly(ethylene

oxide)-block-polyesters with grafted polyamines as supramolecular nanocarrier for efficient siRNA delivery” Biomaterials, 30(2):242-53. Top 25 hottest articles between Oct. and Dec. 2008 in Biomaterials


14

62. Molavi O, Ma Z, Hamdy S, Samuel J, Lavasanifar A* (2009) “Immunomodulatory and

anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124” Immunopharmacology and immunotoxicology, 16:1-14.

63. Patal SK, Lavasanifar A, Choi P* (2008) “Application of Molecular Dynamics

Simulation for predicting the solubilization of water insoluble drugs by self associating poly(ethylene oxide)-b-poly(ε−caprolactone) block copolymers” Biomacromolecules, 9(11):3014-23.

64. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A* (2008) “Disposition of Drugs in

Block Copolymer Micelle Delivery Systems: from Discovery to Recovery” Clinical Pharmacokinetics, 47(10):619-34.

65. Ma Z, Molavi O, Haddadi A, Lai R, Gossage R A., Lavasanifar A* (2008)“Resveratrol

analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol” Cancer Chemotherapy and Pharmacology, 63(1):27-35.

66. Xiong XB, Uludag H, Lavasanifar A* (2008) “Multifunctional polymeric micelles for

enhanced intracellular delivery of doxorubicin to metastatic cancer cells.” Pharmaceutical Research. 25(11):2555-66.

67. Hamdy S, Molavi O, Ma Z, Haddadi A, Ghotbi Z, El-Hasi S, Alshamsan A, Samuel J,

Lavasanifar A* (2008) “Co-delivery of cancer associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity”, Vaccine, 26:5046-5057.

68. Binkhathlan Z, Brocks DR, Lavasanifar A* (2008)“Development of a liquid

chromatography–mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma” Journal of Chromatography B, 869(1-2):31-7.

69. Molavi O, Ma Z, Hamdy S, Samuel J, Lai R, Lavasanifar A* (2008)“Synergistic anti-

tumor effects of CpG oligodeoxynucleotides and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model” Journal of Immunology and Cell Biology, 86(6):506-14.

70. Mahmud A, Xiong XB, Lavasanifar A* (2008) “Development of novel polymeric

micellar drug conjugates with hydrolysable core structure for doxorubicin delivery” European Journal of Pharmaceutics and Biopharmaceutics, 69:923-34. Ranked 36th out of 331 papers published in EJPB in 2008

71. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J* (2008)“Micelles of

poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization, stabilization and controlled delivery of curcumin” Journal of Biomedical Material Research A, 86(2):300-10.


15

72. Molavi O, Ma Z, Lavasanifar A, Kwon GS, Samuel J* (2008)“Development of a polymeric micellar vehicle for the solubilization and controlled delivery of STAT3 inhibitor cucurbitacins” International Journal of Pharmaceutics, 347, 118–127.

73. Aliabadi HM, Romanick M, Desai S, Lavasanifar A* (2008) “Effect of buffer and

antioxidant on stability of a mercaptopurine suspension” American Journal of Health-System Pharmacy 1;65(5):441-7.

74. Mahmud A, Xiong X.B., Aliabadi HM, Lavasanifar A* (2007) “Polymeric micelles for

drug targeting” Journal of Drug Targeting, 15(9)553-584.

75. Açan Clements B, Incani V, Kucharski C, Ritchie B, Lavasanifar A, Uludağ H* (2007) “A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine trade mark 2000 for plasmid delivery to bone marrow stromal cells” Biomaterials 28(31) 4693-4704.

76. Aliabadi HM, Brocks D, Mahdipoor P, Lavasanifar A* (2007) “A novel use of an in vitro

method to predict the in vivo stability of block copolymer based nano-containers.” Journal of Controlled Release. 122(1)63-67.

77. Aliabadi HM, El-Hasi S., Brocks DR, Lavasanifar A* (2008)“Polymeric micellar delivery

reduces nephrotoxicity of cyclosporine A” Journal of Pharmaceutical Sciences. 97(5):1916-1926.

78. Xiong XB, Mahmud, A, Uludag H, Lavasanifar A* (2007)“Conjugation of Arginine-

Glycine-Aspartic acid peptides to poly (ethylene-oxide)-b-poly(ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells” Biomacromolecules, 8(3):874-84. Top 20 most-assessed papers and Top 20 most-cited articles published in 2007 in Biomacromolecules

79. Haddadi A, Elamanchili, P, Lavasanifar A, Das S, Samuel J* (2007) “Delivery of

Rapamycin by PLGA Nanoparticles Increases its Suppressive Activity on Dendritic Cells” Journal of Biomedical Materials Research, 84A(4):885-898.

80. El-hasi S, Astaneh R, Lavasanifar A* (2007) “Solubilization of an amphiphilic drug by

poly(ethylene oxide)-block-poly(ester) micelles” European Journal of Pharmaceutics and Biopharmaceutics, 65(3) 406-413.

81. Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J* (2007) "High-performance

liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin" Biomedical Chromatography, 21(5):546-552.

82. Incani V, Tunis E, Clements BA, Olson C, Kuncharski C, Somayaji V, Lavasanifar A,

Uludag H* (2007) “Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. Journal of Biomedical Materials Research, 81A(2):493-504.


16

83. Aliabadi HM, Elhasi S, Mahmud A, Gulamhusein R, Mahdipour P, Lavasanifar A*

(2007) “Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: The effect of solvent composition on micellar properties and drug loading”. International Journal of Pharmaceutics 329(1-2)158-165.

84. Mahmud A, Xiong XB, Lavasanifar A* (2006) “Novel poly(ethylene oxide)-block-

poly(e-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery” Macromolecules,39(26) 9419-9428.

85. Aliabadi HM, Spencer T, Mahdipour P, Lavasanifar A, Brocks DR, (2006) “Insights into

the effects of hyperlipidemia on cyclosporine A biodistribution and nephrotoxicity” AAPS Journal, 8(4) E672- E681.

86. Molavi O, Shayeganpour A, Somayaji V, Hamdy S, Brocks DR, Lavasanifar A. Kwon

GS. Samuel J* (2006) “A Sensitive and Specific Liquid Chromatography/Mass Spectrometry Method for Quantification of Cucurbitacin I (JSI-124) in Non-Biological Samples and Rat Plasma. Journal of Pharmacy and Pharmaceutical Sciences 9(2): 19-26.

87. Açan B, Bai J, Kucharski C, Farrell L, Lavasanifar A, Ritchie B, Ghahary A, Uludağ H*,

(2006) “RGD Conjugation to PEI Does Not Improve Transfection of Bone Marrow Cells”, Biomacromolecules, 7(5) 1381-1385.

88. Aliabadi HM and Lavasanifar A* (2006) “Polymeric micelles for drug delivery”, Expert

Opinion in Drug Delivery, 3(1):139-62.

89. Mahmud A and Lavasanifar A* (2005) “The effect of block copolymer structure on the internalization of poly(ethylene oxide)-block-poly(ε-caprolactone) micelles by human breast cancer cells”, Colloids & Surfaces B: Biointerfaces, 45(2) 82-89.

90. Aliabadi HM , Brocks DR, Lavasanifar A* (2005) “Polymeric micelles for the

solublization and delivery of Cyclosporine A: Pharmacokinetics and biodistribusion”, Biomaterials, 26(35) 7251-7259.

91. Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A* (2005) “Micelles of methoxy

poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solublization and controlled delivery of cyclosporine A” Journal of Controlled release, 104; 301-311. (Top 10 most cited paper in Journal of Controlled Release in 2005)

92. Adams ML, Lavasanifar A, Kwon GS* (2003) “Amphiphilic block copolymers as self-

associating delivery agents” (minireview). Journal of Pharmaceutical Sciences, 92; 1343-1355. (Top 3 most cited paper in Journal of Pharmaceutical Sciences)

93. Lavasanifar A, Samuel J, Kwon GS* (2002) Poly(ethylene oxide)-block poly(L-amino

acid) micelles for drug delivery. Advanced Drug Delivery Reviews, 54; 169-190.


17

94. Lavasanifar A, Samuel J, Sattari S, Kwon GS* (2002) Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharmaceutical Research, 19; 418-422.

95. Lavasanifar A, Samuel J, Kwon GS* (2002) The effect of fatty acid substitution on the in

vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). Journal of Controlled Release, 79; 165-172.

96. Lavasanifar A, Samuel J, Kwon GS* (2001) “Micelles self assembled from poly(ethylene

oxide)-block-poly(N-hexyl stearate L-aspartamide) through a solvent evaporation method: Effect on solubilization and heamolytic activity of amphotericin B”, Journal of Controlled Release, 77; 155-160.

97. Lavasanifar A, Samuel J, Kwon GS* (2001) “The effect of alkyl core structure on

micellar properties in poly(ethylene oxide)-block-poly aspartic acid derivatives” Colloids & Surfaces B: Biointerfaces, 22; 115-126.

98. Lavasanifar A, Samuel J, Kwon GS* (2000) “Micelles of poly(ethylene oxide)-block-poly

(n-alkyl stearate) l-asparamide: synthetic analogs of lipoproteins for drug delivery”, Journal of Biomedical Materials Research, 52; 831-835.

99. Aramwit P, Yu B, Lavasanifar A, Samuel J, Kwon GS* (2000) “The effect of serum

albumin on aggregation state and toxicity of amphotericin B”, Journal of Pharmaceutical Sciences, 89 (12) 1589-1593.

100. Lavasanifar A*, Ghalandari R, Ataie Z, Zolfaghari ME, Mortazavi SA (1997)

“Microencapsulation of theophylline using ethylcellulose: In vitro drug release and kinetic modeling: Journal of Microencapsulation; 14 (1); 91 – 100.

Papers In Preparation/submitted:

1. M Rezazadeh; J Emami; F Hasanzadeh; A Mostafavi; H Sadeghi; M Minaiyan; M Rostami, A Lavasanifar “Development of novel chitosan-based polymeric micelles for targeted delivery of paclitaxel: Synthesis, characterization, in vitro cytotoxicity and in vivo pharmacokinetic evaluation”, Submitted.

2. Solymani H, Vakili MR, Zhang S., Lavasanifar A. “ABC tri block copolymer micelles as nano-reservoirs for drug solubilization and controlled delivery” In Preparation.

3. SM Garg, MR Vakili, A Lavasanifar, “The Effect of Pendent Group Chemistry on the Stability of Polymeric Micelles based on Functionalized Poly(ε-caprolactone)-block-poly(ethylene oxide): An In Vitro Study” Colloids and Surfaces B, In Preparation 4. N Safaei Nikouei, MR Vakili1, Markian S Bahniuk; Larry Unsworth, A Akbari, J Wu, A Lavasanifar* “Thermo-Reversible Hydrogels Based on Triblock Copolymers of Poly(ethylene glycol) and Carboxyl Functionalized Poly(<epsilon>-caprolactone): The


18

Effect of Carboxyl Group Substitution on the Transition Temperature and Biocompatibility in Plasma" Acta Biomaterilia, submitted.

5. N Safaei Nikouei, and A Lavasanifar* “Triblock Copolymers Based on poly(ethylene glycol) and poly(a-benzyl carboxylate-co-carboxyl)-e-caprolatone for pH and Temperature Responsive Delivery of Macromolecules, In Preparation.

b. Patents/Patent applications 1. Lavasanifar A. and Safaiee Nekoie N. “Novel Biodegradable Thermoresponsive

Hydrogels” US patent application 61/254,478 filed in October 2009.

2. Lavasanifar, A., Xiong, XB “Novel ligand guided poly(ethylene oxide)-block-poly(ester micellar drug conjugates and nano-carriers for targted drug delivery.” PCT paenet application number PCT/CA2007/002298.

3. Lavasanifar A. and Mahmud A. “Novel poly(ethylene oxide)-block-poly(ester) block copolymers with reactive groups on the polyester block for drug delivery. US patent 8,309,515 (granted); Canada patent application No. 2646425 (notice of allowance issued); Eu patent No. EU7710774.6(granted); Japan patent application no. JP 2009-500678 (pending).

4. Lavasanifar A., and Kwon G.S., “Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs” US patent No. 11/569,719. Canada patent application No. 2,580,305.

5. Kwon, G.S., Samuel, J.S., and Lavasanifar, A. Methods and Compositions for Polyene Antibiotics with Reduced Toxicity. US Patent application No. 10/187,317, Filed on June 28, 2001, patent issued on March 10th, 2005.

c. Books and monographs 1. Xiong XB., and Lavasanifar A. “Amphiphilic Block Copolymer Based Nanocarriers for

Drug and Gene Delivery in Intracellular Delivery, Fundamentals and Applications. Springer, Editor: Ales Prokop, 2011; p251-290.

2. Xiong, XB., Uludag, H., Lavasanifar A. “Engineering of Amphiphilic Block Copolymers for Nanoscale Drug and Gene Delivery” in Nanotechnology in Drug Delivery” AAPS and Springer Science, Editor, Mel de Villiers, G.S. Kwon, Chapter 13, 2008 p385-422.

3. Xiong, XB., Aliabadi HM, Lavasanifar A.; “PEO-modified PLAA micelles for drug delivery” in “Nanotechnology and Cancer therapy”, CRC Press, Editor, Mansoor M Amiji, Chapter 18, 2007.


19

d. Abstracts 1. Hoda Soleymani Abyaneh, Mohamadreza Vakili, Fanglin Zhan, Afsaneh Lavasanifar,

“Prepration of Micelle-forming block copolymers as nano-reservoirs for Controlled Drug Release” Annual meeting of CSPS, Montreal, June 2014.

2. Shyam M Garg, Mohamamdreza Vakili, Afsaneh Lavasanifar “Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates for delivery of STAT3 inhibitor JSI-124 to murine B16 melanoma” Annual meeting of the controlled release Society, Chicago, July 2014.

3. Qi Zhang, Mohammadreza Vakili, Afsaneh Lavasanifar “Novel Encapsulation of Arsenic

Trioxide into Polymeric Micelles” Annual meeting of the controlled release Society, Chicago, July 2014.

4. Shyam Garg, Mohammad Reza Vakili, Afsaneh Lavasanifar. The Effect of Core Structure

on the Physicochemical and Biological Stability of Polymeric Micelles based on Poly(ethylene Oxide) and Functionalized Poly(epsilon-caprolactone): an in vitro Study, Annual meeting of CSPS, Vancouver, June 2013.

5. Nazila Safaei Nikouei1, Mohammad Reza Vakili1 and Afsaneh Lavasanifar Development

of thermo-reversible gels based on tri block copolymers of poly(ethylene glycol) and functionalized poly(ε-caprolactone) for drug delivery, Annual meeting of CSPS, Vancouver, June 2013.

6. Hoda Soleymani, Mohammadreza Vakili, Afsaneh Lavasanifar. Role of Stereoregularity

in the Stability of Polymeric Micelles and their Release Profiles, Annual meeting of CSPS, Vancouver

7. Soleymani-Abyaneh H., Vakili M, and Lavasanifar A. “The effect of stereochemistry on

self-association of di and tri block copolymers based on poly(ethylene glycol), poly(lactide) and functionalized poly(e-caprolactone)” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.

8. Safaei Nikouei N, Vakili M, and Lavasanifar A “Development of thermoreversible gels

based on tri block copolymers f poly(ethylene glycol) and functionalized poly(ε-caprolactone) for drug delivery” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.

9. Garg S, Hamdy S, and Lavasanifar A “Polymeric micelles for the Delivery of Stat3

Inhibitor Cucurbitacin I to Tumor Suppressed Dendritic Cells: A Strategy to Enhance the Efficacy of Cancer Immunotherapy” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.


20

10. Shahin M, Soudy R, Kaur K, and Lavasanifar A, “Decoration of Stealth Liposomal Doxorubicin Formulations with Engineered Peptides Targeting Breast Tumors: Evaluation of In Vitro and In Vivo Anti-cancer Activity” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.

11. Falamarzian A, Aliabadi HM, Marcoux, Y, Seubert JM, Uludag H, Lavasanifar A.,

“Effective Down-regulation of Signal Transducer and Activator of Transcription 3 (STAT3) by siRNA Delivery using Lipid Substituted Polyethyleneimines Leads to Cell Death in Wild Type and Doxoxrubicin Resistant Breast Cancer Cells” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.

12. Soleymani-Abyaneh H., Vakili M, and Lavasanifar A. “Preparation of Micelle-forming

ABC Type Tri-Block Copolymers of poly(ethylene glycol), poly(lactide) and poly(α-benazylcarboxylate-ε-caprolactone): The effect of stereo-chemistry on micellar properties in drug delivery” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.

13. Safaei Nikouei N, Vakili M, and Lavasanifar A “Tri Block Copolymers of Poly(ethylene

glycol) and functionalized poly(ε-caprolactone): Synthesis and characterization of their thermo-responsive sol-gel transition” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.

14. Shahin M, Soudy R, Kaur K, and Lavasanifar A, “The effect of breast cancer cell

targeting peptide ligand density on the tumor selective delivery of doxorubicin by stealth liposomal formulations” ” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.

15. Ahmed S, Mathews, A.S., Lavasanifar A, and Kaur K. “Engineering peptide-

nanoconjugates for breast cancer targeting”, Canadian Society for Chemists, May 2012, Calgary.

16. Shahin M, Soudy R, Kaur K, Lavasanifar A “Engineered peptides for breast tumor

targeted delivery of doxorubicin by stealth liposmal formulations: the effect of ligand density” 12th European Symposium on Controlled Drug Delivery, Netherland (April 4-6th), 2012.

17. Zhang, Q.; Xiong, X.-B.; Li, X-F.; Lavasanifar, A.; Le, X.C. Efficient polymeric micelle

encapsulation of p-aminophenylarsine oxide. The Joint 57th International Conference on Analytical Sciences and Spectroscopy and the 3rd Canada-China Analytical Chemistry Conference. Toronto, Canada, August 28-31, 2011. Abstract Book page 75.

18. Zhang, Q.; Xiong, X.-B.; Li, X-F.; Lavasanifar, A.; Le, X.C. Efficient polymeric micelle

encapsulation of p-aminophenylarsine oxide. Macgregor Research Day: Oral presentation. October 11, 2011.


21

19. Shahin M, Soudy R, Kaur K, Lavasanifar A "Engineered peptides for active drug targeting by liposomal carriers of doxorubicin" 9th International Nanomedicine and Drug Delivery Symposium, Salt Lake City, Utah, USA (Oct 15-16), 2011.

20. Garg SM, Xiong XB, Hamdy S, Lavasanifar A Biocompatibility and Biodegradability of

Block Copolymers based on Poly(ethylene oxide) and Functionalized Poly(caprolactone) 9th International Nanomedicine and Drug Delivery Symposium, Salt Lake City, Utah, USA (Oct 15-16, 2011)

21. Safaei Nikouei N, Lavasanifar A, “Tri Block Copolymers of Poly (ethylene glycol) and

Functionalized Poly(ε-caprolactone): Synthesis and Characterization of their Thermo/pH Responsive Assembly” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Montreal, May 2011.(winner of Cedarlane Award of Excellence for poster presentations)

22. Binkhathlan Z, Shayeganpour A, Brocks DR, Lavasanifar A, “Encapsulation of P-

glycoprotein inhibitors in polymeric micelles can reduce doxorubicin-free drug interactions” Annual meeting of the Canadian Chapter of Controlled Release Society, Montreal, May 2011.

23. Garg, S, Xiong, XB, Lavasanifar A, “The Effect of Core Structure on the

Biocompatibility and Biodegradability of Polymeric Micelles based on Functionalized Poly(ethylene Oxide)-block-poly(epsilon-caprolactone): an in vitro Study” International Conference on Materials for Advanced Technologies, July 2011, Singapore.

24. Garg, S, Xiong, XB, Lavasanifar A, “ The Stability and Biocompatibility of Crosslinked

Poly(ethylene oxide)-block-poly(epsilon-caprolactone) Micelles International Conference on Materials for Advanced Technologies, July 2011, Singapore

25. Lavasanifar A., Xiong XB, Ma, Z., Shahin, M., Mathews A.S., Ahmed, S., Kaur, K., "Targeted nanodelivery systems for improving response to cancer chemo and immonotherapy" 15th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.

26. Garg S, Xiong XB, Lu C, Lavasanifar A, “ Application of Click Chemistry in the

Preparation of Novel Core Crosslinked Polymeric Micelles Based on Poly(ethylene oxide)-block-poly(ε-Caprolactone)” 15th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.

27. Patel SK, Lavasanifar A, Choi P* “Prediction of the Solubility of Cucurbitacin Drugs in

Chemically Modified PEO-b-PCL Block Copolymers Using Moelcular Dynamics Simulation”, Canadian Chemical Engineering Conference, Saskatoon, SK, October 2010.

28. Xiong XB, Lavasanifar A*; “Tumor targeted polymeric micelles for co-delivery of

siRNA and anticancer drugs” Annual meeting of the Controlled Release Society,


22

Portland, USA, July 2010 (winner of a travel award from the Canadian Chapter of the Controlled Release Society).

29. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi A, Uludag, H, Lavasanifar *.,

“Down-modulation of Stat3 in B16 melanoma by lipid modified PEI/sirna nano-complexes: Implications in cancer immunotherapy” Annual meeting of the Controlled Release Society, Portland, USA, July 2010(winner of a travel award from the Canadian Chapter of the Controlled Release Society).

30. Falamarzian A, Lavasanifar A* “Synthesis and characterization of novel PEG-PCL

based nano-carriers with acyl and cholesteryl structures for drug solubilization and delivery” Annual meeting of the Controlled Release Society, Portland, USA, July 2010.

31. Binkhathlan Z., ElHasi S., Lavasanifar A*, “Characterization of nano-structures formed

from assembly of poly(ethylene oxide)-b-poly(a-benzyl-e-caprolactone) in water” Annual meeting of the Controlled Release Society, Portland, USA, July 2010 (winner of a travel award from the Canadian Chapter of the Controlled Release Society).

32. Shahin M, Ahmad S, Kaur K, Lavasanifar A* “Synthesis and in vitro Evaluation of

Peptide Decorated Polymeric Micelles for Paclitaxel Delivery to Human Cancer Cells” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada. (winner of a travel award from CSPS).

33. Binkhathlan Z, ElHasi S, Brocks DR, Lavasanifar A* “Characterization of Nano-

carriers Formed from Self Assembly of Methoxy carboxylate-ε-caprolactone) for the Solubilization and in vivo Delivery of Valspodar” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada.

34. Xiong XB, Lavasanifar A* “Tumor Targeted Polymeric Micelles for Co-Delivery of siRNA and Anticancer Drugs: ANew Strategy for Chemo-Sensitization of Resistant Tumors” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada. (winner of a travel award from CSPS).

35. Kaur K*, Ahmed S, Mathews AS, Lavasanifar A “Cancer specific peptides from peptide arrays” Gordon research conference on Peptides, Chemistry & Biology of, Feb 28-March 5th, 2010, CA, USA.

36. Hamdy S, Alshamsan, A, Shayeganpour A, Haddadi A, Aliabadi HM, Lavasanifar A*,

“The immunosuppressive activity of polymeric micellar formulation of Cyclosporin A: in vitro and in vivo studies”. Annual meeting of AAPS, November 2009, Los Angeles.

37. Alshamsan A, Haddadi A, Hamdy S, Samuel J, Uludag H, El-Kadi AOS, Lavasanifar

A* “Targeting dendritic cells with PLGA nanoparticles of anti-STAT3 siRNA breaks


23

cancer-mediated immune tolerance.” Annual meeting of AAPS, November 2009, Los Angeles.

38. Shahin M, Lavasanifar A* “Chemical tailoring of the core structure in poly(ethylene

Oxide)-b-poly(ε-caprolactone) micelles for paclitaxel solubilization and delivery” Annual meeting of AAPS, November 2009, Los Angeles.

39. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* “A comparison between

pharmacokinetics of PSC 833 in the Cremophor EL formulation and polymeric micellar formulation.” Annual meeting of AAPS, November 2009, Los Angeles.

40. Falamarzian A, Kwon GS, Lavasanifar A * “Chemical tailoring of micelle forming

poly(ethylene oxide)-b-poly(ε-caprolactone) block copolymers: Effect on solubilization and hemolytic activity of Amphotericin B” Annual meeting of AAPS, November 2009, Los Angeles.

41. Safaei Nikouei N, Lin B, Sundararaj U, Lavasanifar A* “Development of Novel

Thermoresponsive Hydrogels for Drug Delivery Applications” Annual meeting of AAPS, November 2009, Los Angeles.

42. Molavi O, Mahmud A, Hamdy S, Hung R, Lai R, Samuel J, Lavasanifar A*

“Development of a poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy” Annual meeting of AAPS, November 2009, Los Angeles.

43. Haddadi A, Hamdy S, Ghotbi Z, Samuel J, Lavasanifar A* “Mannose receptor targeting

potentiates immunostimulatory effect of vaccine delivery systems” Annual meeting of AAPS, November 2009, Los Angeles.

44. Zahra Ghotbi, Azita Haddadi, Samar Hamdy, Ryan W. Hung, John Samuel and Afsaneh Lavasanifar. Dendritic cell (DC) targeting with mannan-adsorbed poly (D, L-lactide-co-glycolide) (PLGA) nanospheres. American Association of Pharmaceutical Scientists (AAPS), Los Angeles, November 2009.

45. Abbasi M, Incani V, Lavasanifar A, Uludag H* “siRNA delivery by lipid-modified

poly(l-lysine) for breast cancer therapy” Gene therapy conference, Sandiego, April 2009.

46. von Guggenberg E, Shahhosseini S, Koslowsky I, Lavasanifar A, Murray D, Mercer J*

“Evaluation of novel biodegradable vectors for improved cellular uptake of radiolabeled oligonucleotides” IRSR meeting in Edmonton, July 2009.

47. Koslowsky I, Shahhosseini S, von Guggenberg E, Murray D, Lavasanifar A, Mercer J*

“In vitro evaluation of a block copolymer as a potential transfection agent for [18F] labelled antisense oligonucleotides” 56th SNM annual meeting, Toronto, Canada, June 2009.


24

48. Alshamsan A, Samuel J, Uludağ H , El-Kadi AOS, Lavasanifar A*, “Tumor Apoptosis after STAT3 Knockdown by Nano-Sized siRNA Complexes”, AFPC annual meeting, Halifax, Canada, June 2009 (Winner of the best student presentation for a travel award to AFPC conference).

49. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* “A Comparison between

Pharmacokinetics of Polymeric Micellar Formulation of Cyclosporine A and its more Hydrophobic Derivative PSC 833”, Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.

50. Alshamsan A, Uludağ H, Samuel J, Lavasanifar A*“RNAi-Based Nanomedicine for

Stat3 Knockdown in Melanoma Using Novel Poly(ethylenimine) Derivatives” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.

51. Shahin M, Mahmud A, Lavasanifar A*“Novel Poly(ethylene oxide)-b-poly( -

caproactone-paclitaxel) conjugate micelles: Synthesis, characterization and antitumor activity.” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.

52. Xiong XB, Uludağ H, Lavasanifar A*“Novel Biodegradable Amphiphilic Poly(ethylene

oxide)-block-polyesters with Grafted Polyamine as Supermolecular Nanocarrier for Efficient siRNA Delivery” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.

53. Uludag H, Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A* “Delivery of

siRNA by lipid-modified poly(ethyleneimine): lipid substitution improves siRNA Stability in Serum” Proceedings of the 8th World Biomaterials Congress 2008, Amsterdam, Netherlands.

54. Mahmud A, Molavi O, Falamarzian A, Lavasanifar A*. “Chemical tailoring of the

hydrophobic block in self associating methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) with cholesteryl side chains for the solubilization of STAT-3 inhibitor Cucurbitacin I”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

55. Haddadi A, Ma Z, Hamdy S, Samuel J, Lavasanifar A* “Co-delivery of a new

generation of MUC1 antigens and Toll-like receptor ligands by biodegradable nanoparticles elicit strong T cell responses” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

56. Molavi O, Ma Z, Hamdy S, Samuel J, Lai R, Lavasanifar A* “Synergistic anti-tumor

effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

57. Shahin M, Ma Z, Ahmed S, Kaur K, Lavasanifar A* “Peptide decorated polymeric

micelles for selective intracellular drug delivery to metastatic breast cancer cells”


25

Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

58. Safaei Nikouei N, Lin B, Sundararaj U, Lavasanifar A* “Preparation of

thermoresponsiv hydrogels for regional drug delivery” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

59. Hamdy S, Leila O, Ma Z, Haddadi A, Gobti Z, El Hasi S, Alshamsan A, Samuel J,

Lavasanifar A* “Therapy of established B16 melanoma tumors by vaccination with melanoma antigen co-encapsulated with adjuvant in PLGA nanoparticles” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

60. Ghotbi Z, Haddadi A, Hamdy S, Mahmud A, Samuel J, Lavasanifar A* “Development

of surface-anchored PLGA nanospheres with mannose-receptor ligands for targeting dendritic cells in cancer immunotherapy” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

61. Binkhathlan Z, El Hasi S, Brocks DR, Lavasanifar A* “Polymeric micelles for the

solubilization and delivery of P-glycoprotein inhibtor, PSC 833 (Valspodar)”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

62. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludağ H* “Oleic-acid

and stearic-acid modification of polyethylenimine improved siRNA silencing effect in B16 melanoma”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.

63. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “The effect of drug loading

levels on the in vivo stability and pharmacokinetic profile of micellar nano-containers” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Montreal, Canada.

64. Xiong XB, Lavasanifar A* “Novel RGD4C-modified micellar drug conjugates for

chemosensitization of resistant tumors” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Montreal, Canada.

65. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “Novel use of an in vitro

method to predict the stability of block copolymer based nano-containers” The Proceedings of Thirteenth International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.

66. Mahmud A, Xiong XB, Lavasanifar A* “Self-associating poly(ethylene oxide)-block-

poly( -caprolactone) copolymers with carboxyl, benzyl carboxylate and Doxorubicin


26

side group: Novel micellar nano-containers and drug conjugates” The Proceedings of The Annual meeting of the Controlled Release Society, Long Beach, CA, USA, July 2007.

67. Xiong XB, Mahmud A, Lavasanifar A* “Novel Multifunctional Polymeric Micelles for

Targeted Drug Delivery” The Proceedings of the Annual meeting of the Controlled Release Society, Long Beach, CA, USA, July 2007.

68. Mahmud A, Xiong XB, Lavasanifar A* “Novel poly(ethylene oxide)-block-poly(ester)

block copolymers with aromatic or reactive side groups on the polyester block for drug delivery” Annual meeting of the American Association of Pharmaceutical Scientist (AAPS), San Antonio, Texas, October 2006.

69. Xiong XB., Mahmud A, Lavasanifar A* “RGD-modified poly(ethylene oxide)-poly(ε-caprolactone) micelles for enhanced intracellular drug delivery Annual meeting of the American Association of Pharmaceutical Scientist (AAPS), San Antonio, Texas, October 2006 .

70. Astaneh R, Lavasanifar A*. “Polymeric micelles as new vehicles for the intravenous

administration of amiodarone” Proceedings of the annual meeting of the Controlled Release Society, July 2006, Austria.

71. Haddadi A, Elamanchili P, Lavasanifar A, Samuel J* “Rapamycin Encapsulated in

PLGA Nanoparticles for Delivery to Dendritic Cells: Phenotypic and Functional Aspects, Proceedings of the annual meeting of the Controlled Release Society, July 2006, Austria.

72. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “Novel use of an in vitro

method to predict the stability of block copolymer based nano-containers” Annual meeting of CSPS, Toronto, Canada, June 2006.

73. Sarkhoshfard K, Ghahary A, Uludag H, Lavasanifar A* “Topical delivery of cox-1 and

cox-2 inhibitors by pluronic hydrogels for the prevention of hypertrophic scarring and fibrosis”, Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.

74. Aliabadi HM, Elhasi S, Brocks DR, Lavasanifar A* “Polymeric micellar delivery

reduces the nephrotoxicity of cyclosporine A” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.

75. Elhasi S, Lavasanifar A* “Development of a freeze-thaw method for the preservation of

poly(ethylene)-block-poly(caprolactone) nanocarriers during storage” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.

76. Xiong XB, Mahmud A, Uludag H, Lavasanifar A*“Preparation of RGD-conjugated

poly(ethylene oxide)-block-poly(ε-caprolactone) micelles for enhanced intracellular delivery of anticancer agents” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.(Winner of the best poster presentation by a trainee).


27

77. Aliabadi HM., Spencer T, Mahdipoor P, Lavasanifar A, Brocks DR* “Effect of

hyperlipidemia on cyclosporine A biodistribution” The annual meeting and exposition of American Association of Pharmaceutical Scientists (AAPS), 2005, Nashville, Tennessee, USA.

78. Aliabadi HM, Brocks DR, Lavasanifar A* “Polymeric micelles for the solublization and

delivery of cyclosporine A: Pharmacokinetics and biodistribution studies” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.

79. Mahmud A, Lavasanifar A* “The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.

80. El-Hasi S, Gholamhossein R, Aliabadi HM, Lavasanifar A* “Preparation of

monodispersed polymeric micellar formulations for efficient encapsulation of cyclosporine A through a co-solvent evaporation method” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.

81. Açan B, Bai J, Kucharski C, Farrell L, Lavasanifar A, Ritchie B, Ghahary A, Uludağ, H*

“Cationic polymers as alternatives to viral gene delivery: RGD-conjugation to cationic polymers does not improve DNA delivery, Canadian Biomaterials Society meeting, Waterloo, 2005.

82. Aliabadi HM, Sharifabadi AD, Lavasanifar A* “Methoxy Poly(Ethylene Oxide)-

Poly( -Caprolactone) Copolymer Micelles for the Solubilization and Delivery of Cyclosporine A”. The 2004 Canada-Japan, Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.

83. Mahmud A, Lavasanifar A* “The effect of block copolymer structure on the

internalization of Polymeric Micelles by Human Breast Cancer Cells”. The 2004 Canada-Japan Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada. (Winner of the best student presentation)

84. Haddadi A, Lavasanifar A, Samuel J “Rapamycin in PLGA Nanoparticles Efficiently

Inhibits Maturation of Dendritic Cells as Compared to Rapamycin in Solution” ”. The 2004 Canada-Japan Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.

85. Acan B, Bai J, Kucharski C, Lavasanifar A, Uludag H. Bioaffinity of Peptide Conjugates

of Polyethyleneimine to Bone Marrow Stromal Cells. BIOMED-11 Meeting, Ankara, (September 2004)

86. Haddadi A, Lavasanifar A, Samuel J* “Rapamycin-loaded nanoparticles prepared by


28

solvent evaporation technique: Drug loading and characterization.” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Vancouver, June 9-12., 2004, Journal of Phramacy and Pharmacutical Sciences 7(2)2004.

87. Mahmud A, Lavasanifar A* "Internalization of polymeric micelles by human breast

cancer cells" Presented in the NSERC nano-science poster presentation; Edmonton, AB (Nov 2003).

88. Sharifabadi AD, Lavasanifar A, Samuel J* “Polymeric Micellar Delivery to Dendritic

Cells” Presented in the NSERC nano-science poster presentation; Edmonton, AB (Nov 2003).

89. Lavasanifar A, Samuel J, Kwon GS* “Block Copolymer Micelles for Solubilization and

Delivery of Amphotericin B” Presented in the annual meeting of Canadian Association of Pharmaceutical Scientists, Banff, Alberta, Canada (June 2002).

90. Lavasanifar A, Samuel J, Kwon GS* “Block Copolymer Micelles for the Encapsulation

and Delivery of Amphotericin B” Presented in the annual meeting of the American Association of Pharmaceutical Scientists; Denver (Oct. 2001).

91. Lavasanifar A, Samuel J, Kwon GS; “Block Copolymer Micelles for the Solubilization

and Delivery of Amphotericin B” Presented in the Annual meeting of the Association of the Faculties of Pharmacy in Canada; Saskatoon (June 2000). (Winner of the best poster presentation by a graduate student for AFPC conference)

92. Lavasanifar A, Samuel J, Kwon GS*, “Block Copolymer Micelles for Solubilization

and Delivery of Amphotericin B” Proceedings of the annual meeting of the American Association of Pharmaceutical Scientists (AAPS); Neworleans (Nov. 1999). AAPS Pharm Sci Supplement Volume 3, Issue 3, 2000.

93. Lavasanifar A, Samuel J, Kwon GS*; “Block Copolymer Micelles for Drug Delivery:

Chemical Tailoring of the Alkyl Core Structure”. Annual meeting of the American Association of Pharmaceutical Scientists (AAPS) AAPS Pharm Sci Supplement, Volume 1, Issue 4, 1999.

94. Lavasanifar A, Samuel J, Kwon GS*; “Artificial Lipoproteins for the Delivery of

Amphotercin B”. Proceedings of the annual meeting of the Controlled Release Society, Boston, MA, USA, June 1999. Journal of Controlled Release, Issue 26 (pp 647-648) 1999.

95. Lavasanifar A, Samuel J, Kwon GS*; “Block Copolymer Micelles with Fatty Acid Core

Structure: Synthetic Analogs of Lipoproteins”. Presented in the annual meeting of the American Association of Pharmaceutical Scientists; San Francisco, Nov. 1998.


29

e. Invited speaker

1. Lavasanifar A. “Nanotechnology for Improving Response to Cancer Chemo and Immunotherapy” 4th international conference on Pharmaceutics & Novel Drug Delivery Systems, San Ontonio, USA March 25th, 2014.

2. Lavasanifar A. “Nano-medicine for improved drug performance” College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, August 26, 2013.

3. Lavasanifar A, “Biodegradable polymers for drug and siRNA delivery: Super Medicine” Canadian Biomaterial Society, Student Chapter, Edmonton, Alberta, November 27, 2012.

4. Lavasanifar A, “Nanodelivery systems for cancer chemo and immunotherapy” School of Pharmacy, University of Toronto, Canada, August 2012.

5. Lavasanifar A, “Nanotechnology for cancer chemo and immunotherapy” School of Pharmacy, University of Waterloo, Canada, March 2012.

6. Lavasanifar A, “Novel Self-associating Biodegradable Polymers for Versatile Drug/Gene Delivery Applications” 2nd international conference on Pharmaceutics & Novel Drug Delivery Systems, Feb 20th, 2012, San Francisco, USA.

7. Lavasanifar A, “Nanotechnology for cancer chemo and immunotherapy” Small Talk, National Institute of Nanotechnology, University of Alberta, February 17th, 2012.

8. Lavasanifar A, “Biodegradable polymers for drug and siRNA delivery” Health and Medical Technology Seminar, Alberta Centre for Advanced MNT Products(acamp), December 1, 2011.

9. Lavasanifar A, “Nanomedicine: The medicine of future with improved therapeutic performance” 5th Iranian Controlled Release Conference, Mashhad, Iran, October 4-6th, 2011.

10. Lavasanifar A, “Nanomedicine: The medicine of future with improved therapeutic performance” College of Pharmacy, University of Houston, Houston, TX, USA, March 2nd, 2011.

11. Lavasanifar A, “Targeted nano-carriers for improving response to cancer chemo- and immunotherapy” 15th International Symposium on Recent Advances in Drug Delivery Systems, February 13-16, 2011, Salt Lake City, Utah, USA.

12. Lavasanifar A, “Targeted nano-therapeutics for improving response to cancer chemo- and immunotherapy” Annual meeting of the Canadian Society of Pharmaceutical Scientist, June 2010, Vancouver, Canada.


30

13. Lavasanifar A, “Engineered polymeric micelles for overcoming drug resistance in cancer” Particles2010, May 2010, Orlando, Florida, USA.

14. Lavasanifar A, “Nanotechnology for improving drug performance”, CSPS Webinar, September 2009.

15. Lavasanifar A, “Nano-technology for drug solubilization and delivery” Annual meeting of the association of the Faculties of Pharmacy in Canada, May 2009, Halifax, Canada.

16. Lavasanifar A. “Drug targeting for controlled drug distribution” Annual meeting of the Canadian Society of Pharmaceutical Scientist” May 2008, Banff, Canada.

17. Lavasanifar A. “Engineered nano-delivery systems for chemo-sensitization of resistant tumors. Annual meeting of the Canadian Society of Pharmaceutical Scientist” May 30-June 2nd, 2007, Montreal, Canada.

18. Lavasanifar A. “Polymeric nano-assemblies for targeted drug delivery in cancer” 2006 International conference on Bio and Pharmaceutical Technology, December 18-21, San Diego, CA, USA.

19. Lavasanifar A., Aliabadi HM and Brocks, D. “Polymeric micelles for the tumor targeted delivery of P-gp inhibitors”, Particles 2006, May 13-16, 2006, Orlando, Florida, USA.

20. Lavasanifar A. “Nano-engineered polymeric micelles for drug delivery to resistant tumor” The 2004 Canada-Japan, Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.

21. Lavasanifar A. “Block copolymer micelles: A new generation of colloidal delivery systems” School of Pharmacy, University of the Pacific, Stockton, USA, (2002).

22. Lavasanifar A. “Block copolymer micelles for the encapsulation and delivery of amphotericin B” School of Pharmacy, University of Manitoba, Canada, (2001).

f. Articles in professional journals without review committee 1. Hamdy S, Lavasanifar A, Samuel J* (2004) “Complexity and flexibility of dendritic cell

functions: possible manipulation for effective therapeutic strategy with two opposite outcomes (immunity and tolerance)” Bulletin of the faculty of Pharmacy, University of Cairo, 42 (2) 397-413.

2. Shafiee A*, Lavasanifar A, Pirooznia B, Mafakheri M, Kamal F; (1991); “New Derivatives of Nitroimidazoles: Synthesis, Antimicrobial and Antifungal Activity.” Journal of Science of I.R.I.; 1(3).


31

E. SUPERVISION

a. Post Doctoral fellows (PDF), Research Associates (RA) and Laboratory Technicians Completed:

Name Position Period Project title Current position * Anahita Dehmoobed Sharifabadi

PDF 04/2002-09/2002

Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs

Community Pharmacist in Winnipeg

Anahita Dehmoobed Sharifabadi

PDF 09/2002-09/2004

Polymer based nano-carriers for dendritic cell targeting

Community Pharmacist in Winnipeg

*Zengshuan Ma

PDF 04/2007-04/2008

Development of new nano-formulations for delivery of curcumin and resveratrol

Research associate at the University of Alberta

*Ryan Hung PDF 07/2008-06/2009

Magnetic Resonance Imaging for In Vivo Tracking of Cancer Antigen-Specific T Lymphocytes

Medical Resident at the University of Alberta

*Azita Haddadi

PDF/RA 04/2007-07/2010

Ligand guided nanocarriers for targeted vaccine delivery

Assistant Professor, University of Saskatchwan

* Changuli Lu PDF 09/2008-04/2009

Development of core cross-linked micelles using click chemistry

PDF, University of Toronto

*Anooshirvan Shayeganpour

PDF 08/2008-07/2010

Tumor Targeted nano-delivery systems for improving response to chemotherapy in cancer

PDF/ Faculty of Medicine, U of Alberta

Annu Stella Mathews

PDF 09/2009-08/2010

Engineered peptides for cancer targeting

Research Scientist, Alberta Research Chemicals

* Xiaobing Xiong

PDF/RA 09/2005-08/2011

Development of novel multifunctional polymeric micelles for anticancer drug and siRNA delivery

Research Associate Wake Forest University Health Sciences, NC, USA

*Samar Hamdy

PDF 10/2008-08/2012

Ligand guided polymeric nanocarriers for targeted vaccine delivery in cancer

Community Pharmacist, Edmonton

*Elaine Moase Lab Tech. 02/2010-10/2011

Research Technologist, Merck Sorono, Edmonton

* Mostafa PDF 10/2012- Nanodelivery systems for Looking for employement


32

Shahin 08/2013 detection of metastatic breast tumors

*Mohammadreza Vakili

PDF 06/2011-08/2013

Chemical Tailoring of PEO-poly(ester)s for drug delivery applications


*Principle Supervisor

Significant awards received by the above trainees during their training period: Dr Ryan Hung AHFMR clinical fellowship

Dr Xiao-bing Xiong Best poster presentation in the 2006 annual meeting of the

Canadian Biomaterial Society, Calgary Best poster presentation in the 2006 Research Day, Faculty of Pharmacy, University of Alberta CSPS award for best poser abstract, CSPS annual meeting 2010, Vancouver, Canada.

Dr Samar Hamdy Best poster presentation in the 2009 Research Day, Faculty of Pharmacy, University of Alberta

Dr Mostafa Shahin The 2013 winner of the GattefosséCanada CSPS award in Lipid based drug delivery

Current:

Name Position Period Project title


RA 09/2013 Chemical Tailoring of PEO-poly(ester)s for drug delivery applications

b. Graduate students: Completed:

Name Degree Period Thesis title Current position

Samuel Abraham

MSc 01/2002- 03/2006

Development of nanoparticulate delivery systems for IL-2

Community Pharmacist, Medicine Hat

* Hamidreza Montazeri Aliabadi

PhD 09/2002-09/2007

Polymeric micelles for the solubilization and delivery cyclosporine A as a model P-glycoprotein inhibitor

Research associate, Chemical and Material Engineering, University of Alberta

* Abdullah Mahmud

PhD 09/2002- 03/2008

Novel Polymeric Micellar Drug Conjugates and Nanocontainers for Drug Delivery Applications

Research Scientist, National cancer Institute, Maryland, USA


33

* Reyhaneh Astaneh

Visiting PhD student

01/2005-11/2005

Polymer based nanocarriers for the solubilization and delivery of Amiodarone

Not aware

*# Samar Hamdy

PhD 09/2002-08/2008

Design of cancer vaccines Community Pharmacist, Edmonton

* Sara El-Hasi

MSc 01/2005-12/2008

Block copolymer based nano-carriers for drug delivery

Not aware

Basak Acan PhD 09/2003-01/2009

Gene Delivery to Bone Marrow Stromal Cells by Non-viral Carriers

NSERC post doctoral fellow, Ruger’s University

*# Leila Molavi

PhD 01/2004-09/2009

Delivery of STAT3 Inhibitor Cucurbitacins to Tumor by Polymeric Nano-Carriers: Implications in Cancer Chemo- and Immunotherapy

Assistant Professor, University of Tabriz, Iran

Sarthak Patal PhD 09/2006-12/2009

Molecular Dynamic Simulation for prediction of drug solubility in polymer based nanocarriers

Scientific Officer of a company in India

#Zahra Ghotbi

MSc 01/2004-01/2010

PLGA-based nanoparticles for targeting of dendritic cells in cancer immunotherapy and immunomonitoring

Taking PEBC exams

#Aws Alshamsan

PhD 09/2004-05/2010

Development of stat-3 targeting sirna nano-carriers for cancer therapy

Assistant Professor, King Saud University, Saudi Arabia

Vanessa Incani

PhD 09/2005-

10/2010

Improving Gene Delivery Efficiency by Lipid Modification of Cationic Polymers

Research Scientist, Innovotech Inc., Edmonton, Alberta

*Ziyad Binkhathalan

PhD 09/2005-07/2011

Development of block copolymer based nanocarriers for the solubilization and delivery of valspodar

Assistant Professor, King Saud University, Saudi Arabia

*Mostafa Shahin

PhD 01/2007- 09/2012

Development of polymer and lipid based nano-delivery systems for targeted cancer chemotherapy.

Community Pharmacist, Vancouver

*Arash Falamarzian

PhD 09/2007-07/2013

Lipid modification of polymeric nanocarriers for drug and siRNA delivery

CEO, Gol Daru, Iran

*Nazila PhD 09/2007- Biodegradable block copolymers Community Pharmacist,


34

Safaei Nekouie

as Edmonton

* Principle supervisor # supervisor since 2007

Significant awards received by the above trainees during their training period: Hamidreza Montazeri Aliabadi Rx&D HFR/CIHR graduate scholarship

Queen Elizabeth II Graduate Scholarship

Abdullah Mahmud

Rx&D HFR/CIHR graduate scholarship

Best presentation by a research trainee, International Conference on MEMS, NANO and smart systems, Banff, Alberta

Samar Hamdy CIHR, Rx& D research fellowship.

Izaak Walton Killam Memorial scholarship (the most prestigious graduate scholarship at the University of Alberta).

Second best Poster Award (Dr. L. Chatten Award), Faculty of Pharmacy and Pharmaceutical Sciences Research day, 2007.

Basak Acan CIHR bone research training award

Rx&D/CIHR graduate scholarship

Queen Elizabeth II graduate scholarship

Leila Molavi Iranian Government Scholarship

Rx&D HFR/CIHR graduate scholarshipDr.

Prize for the best graduate poster presentation, Faculty of Pharmacy Research day, 2005 and 2008

AFPC Canadian Foundation for Pharmacy National Student Poster Award.

Aws Alshamsan Saudi Government Scholarship

Gattefossé Canada CSPS Award in Lipid-Based Drug Delivery (national wide), 2010, 13th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting.


35

Vancouver, British Columbia, Canada

AFPC Travel Award for Best Graduate Student Poster, Faculty of Pharmacy and Pharmaceutical Sciences Research Day.

1st Place Wu Hong Memorial Poster Prize, Faculty of Pharmacy and Pharmaceutical Sciences Research Day, 2008.

Dr. Nojaim Memorial Award for Best Graduate Student Poster Presentation, Faculty of Pharmacy and Pharmaceutical Sciences Research Day, 2006.

Ziyad Binkhathlan Saudi government scholarship

Award for poster presentation in Faculty of Pharmacy research day in 2008 and 2009.

Travel ship award for poster presented in the annual meeting of the Controlled Release Society (CRS).

Mostafa Shahin

Egyptian government scholarship WCHRI trainee travel fund, Women and children’s health research institute (WCHRI), Canada. Oct 2012 WCHRI trainee travel fund, Women and children’s health research institute (WCHRI), Canada. June 2012 2nd best poster presentation (senior graduate students’ group) in the research and development day of the Faculty of Pharmacy and Pharmaceutical sciences, Faculty of Pharmacy, University of Alberta, Canada. 2011 ICR publication prize for article entitled "Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.", published in Biomaterials. 2011 Aug;32(22):5123-33, Canadian Institute of Health Research (CIHR), Canada. 2011 CSPS annual meeting Travelship award, Controlled release Society, Canada 2010 BIOTEC annual meeting Travelship award, American Association of Pharmaceutical Sciences (AAPS), USA 2009 President‘s Doctoral prize of Distinction, University of Alberta, Canada. 2009 Frederick Banting and Charles Best Canada Graduate Scholarships - Doctoral Award, Canadian Institute of Health Research (CIHR), Canada 2009-2010 Residence Community Award (Outstanding Volunteer), Residence Services, University of Alberta, Edmonton, Canada. 2009


36

Professional Development and Travel Grant, Graduate student association (GSA), University of Alberta, Canada. 2008 Shoppers drug mart graduate scholarship, Faculty of pharmacy and pharmaceutical sciences, University of Alberta 2008. Taiho/Alberta Endowed Fund Travel Assistant award, Faculty of pharmacy, university of Alberta 2008 Gattefossé Canada CSPS Award in Lipid-Based Drug Delivery 2013

Arash Falamarzian Best Overall Platform $800+AFPC Travel Award (Top‐ranked graduate student), Faculty of Pharmacy and Pharmaceutical sciences research day 2010 Alberta Cancer board graduate studentship award, Edmonton, Alberta (Sep 2010-Aug 2012) $20,000/year over two years Alberta Cancer board graduate studentship award, Edmonton, Alberta (Sep 2008-Aug 2010) $20,000/year over two years Dean’s special recruitment scholarship award, Faculty of Pharmacy and Pharmaceutical sciences, University of Alberta (Sep 2007-Aug 2008) $15,000

Nazila Safaei Nekouie Cedarlane Award of Excellence for poster presentations in the

annual meeting of CSPS in 2011

Current:

Name Degree Period Thesis title

*Shyam Garg

PhD 01/2010- Rational design and development of poly(ester) based nanocarriers for targeted cancer therapy

Qi Zhang PhD 09/2010- Development of new polymeric micellar formulations for tumor targeted delivery of arsenic trioxide derivatives

*Hoda Soleymani Abyaneh

PhD 09/2011- Development of polymeric micellar formulations for effective drug delivery to tumor micro-environment

Zhara Shire PhD 09/2012- Development of nanocarriers for synthetic lethal combination therapy of cancer


37

*Igor Moura de Paiva

PhD 09/2014- Polymeric micelles for siRNA Delivery

* Principle supervisor

Significant awards received by the above trainees during their training period: Shyam Garg JN Tata Trust Endowment Scholarship 2009-2010

Alberta Cancer Foundation Graduate Studentship 2010 CIHR Institute of Cancer Research Travel Award Dr. John Samuel Memorial Graduate Scholarship Graduate Student Teaching Award 2012 Golden Key Research Grant 2011 Dr. Ronald Micetich Memorial Graduate Scholarship 2012 Dr. Ed Knaus Graduate Scholarship in Pharmaceutical Research 2012. Alberta Innovates Health Solutions graduate stundetship. Ranked 5th among 94 applications. April 2013.

Qi Zhang Medical Sciences Graduate Program Scholarship 2012.

Hoda Soleymani Abyaneh

Biochem Pharma Graduate Scholarship, University of Alberta, 2012. Graduate Research Assistantship Award, University of Alberta, 2012. Graduate Research Assistantship Award, University of Alberta, 2011. Mike Wolywik Graduate students ship (2013) WCHRI Graduate Studentship (2014)

c. Undergraduate students

Name Major Period Title of project Current position

Sabrina Rashid Science 05/2003- 09/2003

Development of nanoparticulate delivery systems for cancer immunotherapy

Not Aware

*Rashida Gholamhossein

Pharmacy 05/2004-09/2004

Polymeric micelles for the solubilization and delivery hydrophobic drugs

Community pharmacist


38

*Homun Yee Science 09/2009- 03/2010

Chemical tailoring of micelle forming PEO-poly(ester) block copolymers

BSc Student, University of Alberta

* Shirley Zhang Pharmacy 06/2013-08/2013

Chemical tailoring of micelle forming PEO-poly(ester) block copolymers

Pharmacy student

*Amir Soleymai

Science 05/2014- Development of nanoparticles for STAT3-inhibtors

Chenzhen Zhang

Pharmacy-China

06/2014- Peptide modified polymeric micelles for drug targeting to metastic cancer.

*Principle supervisor Significant awards received by the above trainees during their training period: Rashida Gholamhossien - Best student presentation by an undergraduate student, Faculty of

Pharmacy Research Day, 2004

Homun Yee

- AHFMR summer studentship, 2009

d. Visiting researchers

Name Field Period Title of project Position

Dr Min Han Pharmacy 06/2012-11/2013

Mitocans for drug resistant tumors

College of Pharmaceutical Sciences, Zhejiang University, China

Dr Soheyla Honary

Pharmacy 01/2013-12/2013

Experimental design for optimization of polymeric micellar formulations.

Associate professor, Mazandaran University of Medical Sciences, Iran

Dr Alireza Shafatiee

Pharmacy 08/2014-07/2015

Stero-active polymers in drug delivery

Professor, Dr Beheshti University of Medical Sciences, Iran

e. Examining Committees:


39

Candidate Degree and exam

Date Supervisor Faculty/ department

Gary Van D PhD, Defense 09/2003 D. Wishart Pharmacy Saidreza Harirfroush PhD, Candidacy 12/2003 F. Jamali Pharmacy Paras Nayer MSc, Defense 01/2005 J. Samuel Pharmacy Tina Grant PhD, Candidacy 07/2005 F. West Chemistry Saidreza Harirfroush PhD, Defense 12/2005 F. Jamali Pharmacy Welson Wang PhD, Candidacy 05/2006 M. Suresh Pharmacy Ali Rostami MSc, Defense 08/2006 F. West Chemistry Anooshiravan Shayganpour

PhD, Candidacy 12/2006 D. Brocks Pharmacy

Praveen Elemanchili PhD, Defense 03/2007 J. Samuel Pharmacy Basak Acan Clements PhD, Candidacy 05/2007 H. Uludag Pharmacy/Chemical

Engineering Arthur Okumo MSc, Defense 09/2007 R. Loebenberg Pharmacy Aws Alshamsan PhD, Candidacy 09/2007 A.El-Kadi Pharmacy Tina Grant PhD, Defense 11/2007 F. West Chemistry Sartak Patel PhD, candidacy 11/2007 P. Choi Chemical Engineering Weinan Hu PhD, defense 12/2007 H. Uludag Chemical Engineering Jenifer Hare PhD, Candidacy 12/2007 T. Allen Pharmacology Anooshiravan Shayganpour

PhD, defense 02/2008 D. Brocks Pharmacy

Reem Beleid MSc Defense 03/2008 K. Kaur Pharmacy Ingrid Koslowsky PhD, Candidacy 06/2008 J. Mercer Pharmacy Welson Wang PhD. Defense 08/2008 M. Suresh Pharmacy Sufeng Zhang Ph.D. Defense 09/2008 H. Uludag Chemical Engineering Sheema Afshar PhD, Candidacy 11/2008 T. Yeung Chemical Engineering Sahar Ahmed PhD, Candidacy 03/2009 K. Kaur Pharmacy Vannesa Incani PhD, Candidacy 06/2009 H. Uludag Pharmacy/Chemical

Engineering

M. Abbasi PhD, Candidacy 07/2009 H. Uludag Chemical Engineering

Ingrid Koslowsky PhD, Defense 06/2010 J. Mercer Pharmacy Gagandeep Kharaud MSc. Defense 08/2010 K. Kaur Pharmacy Jigar Patal PhD, Defense 10/2010 D. Brocks Pharmacy Vanessa Incani PhD, Defense 10/2010 H. Uludag Pharmacy Maryam Kabiri PhD, Candidacy 11/2010 L. Unsworth Chemical Engineering Jennifer Hare PhD, Defense 04/2011 T. Allen Pharmacology Krishna Chaitanya MSc, Defense 08/2011 K. Kaur Pharmacy Dharmendra Raghuwanshi

PhD, Candidacy 09/2011 K. Kaur Pharmacy

Dharmendra Raghuwanshi

PhD, Defense 07/2012 K. Kaur Pharmacy


40

Krishna Chaitanya MSc, Defense 08/2012 K. Kaur Pharmacy Minashree Singh MSc, Defense 08/2012 K. Kaur Pharmacy Rawabi Qadhi MSc, Defense 10/2012 J. Seubert Pharmacy Arash Panahifar PhD, Candidacy 10/2012 M. Doschak Pharmacy Foroughalsadat Sanaee

PhD, Candidacy 11/2012 F. Jamali Pharmacy

Basak Shahin MSc, Defense 06/2013 H. Uludag Biomedical Engineering Maryam Kabiri PhD, Defense 03/2014 L. Unsworth Chemical Engineering Ali Akbari PhD, Candidacy 03/2014 Wu Agriculture and

Nutrition Forough Sanaiee PhD, Defense 03/2014 M. Jamali Pharmacy Arash Panahifar PhD, Defense 07/2014 M. Doschack Pharmacy Waheed Asghar PhD, Canidacy 09/2014 M Jamali Pharmacy

f. Supervisory committees:

Candidate Degree Supervisor Date

Paras Nayer MSc J Samuel 2002-2005 Mayowa Adelyde PhD M Suresh 2004-2007 Reem Belidad MSc K. Kaur 2005-2008 Arthur Okumu MSc R. Leobenberg 2006-2007

Dharmendra Raghuwanshi

PhD K. Kaur 2007-2012

Gagandeep Kharaud MSc K. Kaur 2008-2010 Jigar Patal PhD D. Brocks 2008-2010 Meysam Abbasi PhD H. Uludag 2009-2009 Rawabi Qahdi MSc J. Seubert 2009-2012 Maryam Kabiri PhD L. Unswarth 2010-present Hashem Etayash MSc K Kaur 2011-2012 Basak Shahin PhD H Uludag 2012-2013 Jieyu Zuo MSc R Loebenberg 2012-present Ali Akbari PhD Wu 2013-present Yougota MSc K Kaur 2014- Waheed Asghar PhD M Jamali 2014-

A. COMMITTEES a. At faculty and University level

III. SERVICE


41

2003-2007 Research day committee (chair)

2004-2007 Seminar series committee (chair)

2004-2005 Appeals committee (member)

2004-2009 Graduate studies committee (member)

2006-2008 Curriculum committee (member)

2007-2009 Faculty Evaluation committee (member)

2008-2009 Admission committee (member)

2009-2011 Assessment committee (member)

2011-Present Faculty Development Seminar committee (chair)

2011-present Curriculum committee (member)

2011-present NMR committee (chair)

2011-2 Search committee for recruitment to a faculty position in drug delivery

2013 Faculty Retreat (co-Chair)

2013 Search committee for recruitment to a faculty position in drug delivery

2013-2014 co-Chair of Green and Gold Student Leadership and Professional Development Grant Committee

2014 Member of the Animal Care and Use Committee

2014 Chair of the Faculty of Pharmacy Committee restructure Task Force

b. At national/international level 2004 Technical committee of the Canada-Japan conference on MEMS,

NANO and smart systems, Banff, Alberta, Canada

2004 Representing NanoPharm group of the faculty of Pharmacy

2006 Organization of the poster competition in annual meeting of the Association of the Faculties of Pharmacy (AFPC) in June May 2006, Edmonton, Alberta

2006 Chair of Cancer Targeting Session in Particles 2006, May 13-16 Orlando, Florida

2006 Organization committee and chair of a session entitled “Polymeric micelles in cancer therapy” in “International conference on Bio and Pharmaceutical Technology”, December 18-21, 2006, San Diego.

2009 Organization committee and chair of a session entitled “Drug absorption and distribution” in annual CSPS meeting, May 22-25, 2009, Banff

2010 Organization committee and chair of a session entitled “New Directions in Clinical Applications of Delivery Systems for Cancer Treatment and


42

Diagnosis” in annual CSPS meeting, June 2-6, 2010, Vancouver.

B. REVIEWING SERVICES

a. At faculty level 2002-2005 Contribution as a judge in compounding competition 2004-2006 Contribution as a judge for evaluation of the poster and podium

presentations in Research Day, Faculty of Pharmacy & Pharmaceutical Sciences

2006 and 2011 Contribution as a presenter in Career night for undergraduate students

b. At the University level 2011 Contribution as a reviewer in the internal review of CIHR grant

application by Dr Gary Eitzen entitled: “Identification of novel Rho GTPase inhibitors”

2012 Internal review of a CIHR grant Entitled “Phenylalkylhydrazine drugs and neuropsychiatric disorders” by Glen Baker

2013 Internal reviewer on PhD proposal for Ms. Valencia Serna Juliana for Biomedical Engineering Department

2014 Internal review of a CIHR program grant related to Dr Lai

c. At national/international level 2007-2010, 2014 Committee member for the pharmaceutical sciences panel of the CIHR

2006 External reviewer for Canadian Foundation for Innovation (CFI)

2007 External reviewer for The Welcome Trust, London, UK.

2008 External reviewer for Natural Science and Engineering Council of Canada (NSERC)

2008-2009 External reviewer for Saskatchewan Health Research Foundation 2009 Committee member for the National Cancer Institute of Canada

(NCIC). Panel G1 (Experimental Therapeutics, Medicinal Chemistry and Drug Development)

2009 External reviewer for Natural Resources and Applied Sciences (NRAS), Province of British Columbia

2009 Reviewer for the selection of best paper by graduate students at AFPC conference

2010 Reviewer for AFPC new investigator award in 2010


43

2010 External Reviewer for NSERC discovery grant

2011 External reviewer for Danish Council for Independent Research/Natural Sciences

2011 Review of file for tenure promotion related to Dr Laired Forrest, Department of Pharmaceutical Chemistry, University of Kansas.

2012, 2013, 2014 Ad Hoc member of the GDD panel in NIH

2013 Reviewer for the promotion of Dr David Dubins to the Rank of Senior lecturer in Faculty of Pharmacy, University of Toronto

d. External examiner on PhD thesis 2011 Enzymatically active probiotics for topical and oral therapy” by

Mitchell Lawrence Jones, March 2011, From Department of Biomedical Engineering of McGill University, Supervisor Dr Sataya Prakash

2011 Development and characterization of intravesical mucoadhesive nanoparticulate formulations of paclitaxel and docetaxel for postoperative chemotherapy in non-muscle invasive bladder cancer” by Clement Mugabe, July 2011, from University of British Columbia, Supervisor Dr Helen Burt

2012 Novel Polysaccharide based polymers and nanoparticles for controlled delivery of drugs and imaging agents”, Faculty of Pharmacy, University of Toronto, August 2012. Supervisor Dr Shirley Wu.

2013 A multifunctional nanoparticle formulation for siRNA delivery targeting neurodegenerative disease and cancer, January 2013. Department Biomedical Engineering, Faculty of Medicine. McGill University, Supervisor Dr Satya Prakash,

2013 Development of Amino acid substituted Gemeni Surfactant based non-invasive Non-viral Gene Delivery Systems, August 2013, College of Pharmacy and Nutrition, University of Saskatchewan, Supervisor Dr Ildiko Badea.

C. CONSULTING SERVICES TO INDUSTRY

2002-2003 Development of water soluble formulations for intravenous administration of drugs with limited biological half-lives

2006 Novopharm, Assessing the stability of 6-Mercaptopurine suspensions


44

2008 University of Alberta hospital, Assessing the stability of compounded thioguanine suspensions

2010-present Scientific Chief officer, Meros Polymers Inc.

D. TEACHING a. Undergraduate courses (Current)

Course Lecture hours-Lab hours Role

Pharmaceutics I (PHARM 331) 20 h-12h Contributor

Pharmaceutics II (PHARM 361) 8 h-24h Contributor-Coordinator

Pharm 341 2h Contributor

b. Graduate courses (Current)

Course Lecture hours Role

Advanced drug delivery systems (PHARM 610)

12h Contributor-coordinator

Directed project (Pharm 694) 20h Contributor

Biomaterial Science (CHE 582) 2 h Contributor

afsaneh lavasanifar, curriculum vitea - university of … · afsaneh lavasanifar, curriculum vitea...

Documents